Sun Pharmaceutical Industries, a company in the Pharmaceuticals industry, reported revenue of ₹16,199 crore and net profit of ₹1,995 crore for the September 2026 quarter.
Sun Pharmaceutical Industries (NSE: SUNPHARMA) closed at ₹1,884.90 on 20 Nov 2026, up 6.0% over the past year. Its market capitalisation is ₹4,52,251 crore and it trades at 36.8 times earnings.
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.